Instruction for use: Anaferon

Dosage form: lozenges

ATX

J05AX Other antivirals

Pharmacological group:

Immunomodulators. Antiviral drugs [Other immunomodulators]

The nosological classification (ICD-10)

A49.9 Bacterial infection, unspecified: Chronic bacterial infection; Chronic bacterial infections; Anaerobic bacterial infection; Bacterial superinfection; Acute bacterial infection; Bacterial infections of severe course; Intrahospital infections; Gram-negative aerobic pathogen; Secondary bacterial infections; Infections in Patients with Weakened Immunity; Infections in surgery; Postinfectious glomerulonephritis

A60 Anogenital herpetic viral infection [herpes simplex]: Herpes simplex genitalis; Banal recurrent genital herpes; Secondary genital herpes; Genital herpesvirus infection; Genital herpetic infections; Genital herpes; Herpes genitalia; Genital herpes; Herpes simplex organs; Herpetic lesions of the mucocutaneous urinary organs; Herpetic lesions of the genitals; Primary genital herpes; Primary herpes simplex; Simple herpes extragenital and genital localization; Recurrent genital herpes; Recurrent herpes of genital organs; Herpes of the lips and genitals

A84 Tick-borne viral encephalitis: Tick-borne encephalitis; Tick-borne encephalitis

B00 Infections caused by the herpes simplex virus [herpes simplex]: Herpes simplex; Herpes virus; Herpes simplex virus; Herpes simplex virus type I and II; HSV; Herpes; Herpes simplex / herpes simplex /; Herpes lips; Herpes simplex; Herpes in patients with immunodeficiency; Labial herpes; Acute herpetic disease of the mucous membranes; Herpes simplex; Herpes simplex skin and mucous membranes; Herpes simplex with skin and mucous membrane damage; Recurrent herpes; Urogenital herpetic infection; Chronic recurrent herpesvirus infection; Herpes-viral infections of various localizations

B00.9 Herpetic infection, unspecified: Herpes face; Herpes mucous membranes; Herpes-viral infections; Herpes-viral infections of various localizations; Herpetic infection; Herpetic infections; Herpetic lesions; Latent herpetic infection; Neonatal herpes; Recurrent herpetic infection; Chronic recurrent herpesvirus infection; Chronic recurrent herpetic infection; Acute herpetic disease of the mucous membranes; Recurrent herpes

B01 Varicella [varicella]: Chicken pox; Newborn chickenpox; Varicella Zoster; Smallpox chickenpox; Herpes Varicella zoster

B27 Infectious mononucleosis: Mononuclear angina; Adenosis multigandular; Lymphoid cell aneurysm; Monocyte angina; Pfeiffer's disease; Türkic Disease; Filatova's disease; Pfeiffer's fever; Lymphoblastosis benign acute; Infectious lymphomononucleosis; Fever; Fever glandular idiopathic; Complications of infectious mononucleosis

B33 Other viral diseases, not elsewhere classified

B34 Viral infection of unspecified site: Viral respiratory tract infections; Infections viral; Viral infection; Viral infections

B34.1 Enterovirus infection, unspecified

B34.2 Coronavirus infection, unspecified

B34.8.0 * Rotavirus infection, unspecified

D84.8 Other specified immunodeficiency disorders: Immunodeficiency due to loss of protein; Immunodeficiency states secondary; Immunodeficiency states with protein loss; Secondary Immune Deficiency; Secondary immunodeficiency status; Secondary immunodeficiency states; Secondary immunodeficiency; Acquired immunodeficiency; Syndrome of secondary immunodeficiency; Secondary immunodeficiencies; Immunodeficiency states primary

J06 Acute upper respiratory tract infections of multiple and unspecified locations: Frequent colds of viral diseases; Infections of ENT organs; Acute respiratory illness of influenza nature; Pain for colds; Acute catarrhal disease; Cold; Colds; Colds; Respiratory infection; Seasonal catarrhal disease; Seasonal colds; Pain in infectious and inflammatory diseases of the upper respiratory tract; Bacterial infections of the upper respiratory tract; Bacterial infections of the respiratory system; Viral respiratory disease; Viral respiratory tract infections; Inflammatory disease of the upper respiratory tract; Inflammatory diseases of the upper respiratory tract; Inflammatory diseases of the upper respiratory tract with difficult to separate sputum; Inflammatory respiratory disease; Secondary infections for colds; Difficult sputum separation in acute and chronic respiratory diseases; Upper respiratory tract infections; Infections of the upper respiratory tract; Respiratory tract infections; Respiratory and lung infections; Infectious-inflammatory diseases of the upper respiratory tract; Infectious-inflammatory diseases of the upper respiratory tract and ENT organs; Infectious-inflammatory diseases of the upper respiratory tract in adults and children; Infectious-inflammatory diseases of the upper respiratory tract; Infectious inflammation of the respiratory tract; Respiratory tract infection; Qatar upper respiratory tract; Catarrh of the upper respiratory tract; Catarrh of the upper respiratory tract; Catarrhal phenomena from the upper respiratory tract; Cough in diseases of the upper respiratory tract; Cough for colds; ARVI; ARI; ARI with phenomena of rhinitis; Acute respiratory infection; Acute infectious-inflammatory disease of the upper respiratory tract; Acute respiratory disease; Persecution in the throat or nose; Respiratory and viral infections; Respiratory diseases; Respiratory infections; Recurrent respiratory tract infections; Secondary infections with influenza; Influenza states; Feverish conditions for influenza

J11 Influenza, virus not identified: Influenza; Influenza in the early stages of the disease; Influenza in children; cold in the chest; Begins flu-like condition; Acute disease parainfluenza; parainfluenza; parainfluenza state; influenza epidemics; The pains of the influenza

Composition

Tablets for resorption - 1 table.

Antibodies to human gamma interferon are affinity purified (lactose monohydrate is applied in the form of a water-alcohol mixture with a content of not more than 10-15 ng / g active form of the active substance) 0.003 g

Auxiliary substances: lactose monohydrate 0.267 g; MCC - 0.03 g; Magnesium stearate - 0.003 g.

Description of dosage form

Tablets for resorption of flat-cylindrical shape, with a risk and facet, from white to almost white.

On the flat side, the inscription "MATERIA MEDICA" is painted with a risk, on the other side - "ANAFERON".

Pharmachologic effect

Mode action - immunomodulating.

Pharmacodynamics

With preventive and therapeutic use, the drug has an immunomodulatory and antiviral effect. Effective against influenza viruses (including avian influenza), parainfluenza, herpes simplex virus types 1 and 2 (labial herpes, genital herpes), other herpes viruses (chicken pox, infectious mononucleosis), enteroviruses, Tick-borne encephalitis virus, rotavirus, coronavirus, calicivirus, adenovirus, RS (respiratory syncytial) virus. Reduces the concentration of viruses in the affected tissues, affects the system of endogenous interferons and conjugated cytokines, induces the formation of endogenous "early" interferons (IFN α / β) and gamma-interferon (IFN-γ).

Stimulates the humoral and cellular immune response. Increases the production of antibodies (including secretory IgA), activates the functions of T-effectors, T-helpers (Tx), normalizes their ratio. Increases the functional reserve of Tx- and other cells involved in the immune response. It is the inducer of the mixed Tx1 and Tx2-type immune response: it increases the production of cytokines Tx1 (IFN-γ, IL-2) and Tx2 (IL-4, -10), normalizes (modulates) the balance of Tx1 / Tx2 activity. Increases the functional activity of phagocytes and EK-cells (natural killers). It has antimutagenic properties.

Indications for the preparation Anaferon

Prevention and treatment of ARVI (including influenza);

Complex therapy of infections caused by herpesviruses (infectious mononucleosis, chicken pox, labial herpes, genital herpes);

Complex therapy and prevention of recurrences of chronic herpesvirus infection, incl. Labial and genital herpes;

Complex therapy and prevention of other acute and chronic viral infections caused by tick-borne encephalitis virus, enterovirus, rotavirus, coronavirus, calicivirus;

Application in the complex therapy of bacterial infections;

Complex therapy of secondary immunodeficiency states of different etiology, incl. Prevention and treatment of complications of viral and bacterial infections.

Contraindications

Increased individual sensitivity to the components of the drug;

Children under the age of 18 (the use of the drug Anaferon for children is indicated).

Application in pregnancy and breastfeeding

The safety of Anaferon in pregnant women and during lactation has not been studied. If necessary, taking the drug should take into account the risk / benefit ratio.

Side effects

When using the drug for the indicated indications and in the indicated dosages, side effects were not revealed. Possible hypersensitivity reactions to the components of the drug.

Interaction

There have been no incidents of incompatibility with other drugs to date. If necessary, the drug can be combined with other antiviral, antibacterial and symptomatic agents.

Dosing and Administration

Inside, single dose - 1 table. Outside eating (keep in mouth until completely dissolved).

ARVI, influenza, intestinal infections, herpesvirus infections, and neuroinfections. Treatment should be started as soon as possible - when the first signs of acute viral infection appear according to the following scheme: the first 2 h - 1 table. Every 30 minutes; Then during the first day - 3 more doses at regular intervals. From 2 days and further take 1 tab. 3 times a day until complete recovery. If there is no improvement on the 3rd day of treatment, you should consult your doctor. In the epidemic season with a preventive goal - 1 table. Daily for 1-3 months.

Genital herpes. When acute manifestations of genital herpes are taken at regular intervals according to the following scheme: 1-3 day - 1 table. 8 times a day, then 1 table. 4 times a day for at least 3 weeks. For the prevention of relapse - 1 tab. in a day. The recommended duration of a preventive course is determined individually and can reach 6 months.

With the use of the drug for the treatment and prevention of immunodeficiency states, in the complex therapy of bacterial infections - take 1 table. in a day.

If necessary, the drug can be combined with other antiviral and symptomatic agents.

Overdose

There have been no cases of overdose to date.

In case of an accidental overdose, dyspeptic events due to the excipients included in the formulation are possible.

Special instruction

The composition of the drug includes lactose monohydrate, and therefore it is not recommended for patients with congenital galactosemia, glucose malabsorption syndrome, or with congenital lactase insufficiency.

Release Form

Lozenges. For 20 tablets. In a planar cell packaging made of PVC film and aluminum foil. For 1, 2 or 5 contour squares are placed in a pack of cardboard.

Manufacturer

OOO NPF Materia Medica Holding.

Conditions of supply of pharmacies

Without recipe.

Storage conditions of the drug Anaferon

At temperatures not higher than 25 ° C, in the original packaging.

Keep out of the reach of children.

Shelf life of the drug Anaferon

3 years.

Do not use after the expiry date printed on the package.